Revolution Medicines, Inc. RVMD
At closeNov 10, 2026, 7:04 PM EST
After hours · Nov 10, 7:04 PM ET
- YTD
- +142.39%
- 1 year
- +207.76%
- Market cap
- 41.76B
- Revenue (ttm)
- 197.56M
- EPS (ttm)
- -9.13
- Shares out
- 216.29M
- Forward P/E
- -62.27
- YTD return
- +142.39%
- 1-year return
- +207.76%
- Volume
- 2.07M
- Avg volume
- 2.07M
- Open
- 197.31
- Previous close
- 200.15
- Day's range
- 189.76 – 198.95
- 52-week range
- 62.29 – 224.31
- Beta
- 1.43
- Analysts
- Strong Buy
- Price target
- 274.84 (+42.4%)
- Earnings date
- Feb 24, 2027
5D -4.60 (-2.33%)
Key statistics
- Enterprise value
- 40.85B
- PEG ratio
- 0.00
- Price / sales
- 211.37
- Price / book
- 17.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -886.29M
- Total cash
- 3.65B
- Total debt
- 1.21B
- Return on equity
- -93.56%
- Short % of float
- 6.31%
- 50-day average
- 196.73
- 200-day average
- 158.23
Analyst view
Consensus: strong buy
- Target (low)
- 179.00
- Target (mean)
- 274.84
- Target (high)
- 350.00
- Strong buy5
- Buy19
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -1.15.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -1.52 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -2.35 | -1.90 | +0.45 | +19.15% |
| Aug 5, 2026 | Jun 30, 2026 | -2.04 | -3.06 | -1.02 | -50.00% |
| May 6, 2026 | Mar 31, 2026 | -1.84 | -2.29 | -0.45 | -24.46% |
| Feb 25, 2026 | Dec 31, 2025 | -1.58 | -1.86 | -0.28 | -17.72% |
| Nov 5, 2025 | Sep 30, 2025 | -1.42 | -1.61 | -0.19 | -13.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 5, 2026 | TD Cowen | main | Buy | Buy |
| Nov 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 5, 2026 | Piper Sandler | main | Overweight | Overweight |
| Nov 5, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 5, 2026 | Guggenheim | main | Buy | Buy |
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revmed.com
News
Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript 
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet 
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy? 
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug 
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $350 
TD Cowen Maintains Buy on Revolution Medicines, Raises Price Target to $270 
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321 
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It 
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake 
Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $222
Your note
Sign in to keep a note on RVMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERS JACK LEE | Chief Financial Officer | Sale | Jun 23, 2026 | 123,269 |
| BORISY ALEXIS | Director | Stock Award(Grant) | Jun 17, 2026 | 2,340,080 |
| GOLDSMITH MARK A | Chief Executive Officer | Sale | Aug 20, 2026 | 0 |
| HORN MARGARET A | Chief Operating Officer | Sale | Jun 16, 2026 | 154,647 |
| HORNING SANDRA | Director | Stock Award(Grant) | Jun 17, 2026 | 97,765 |
| KELSEY STEPHEN MICHAEL | Officer | Sale | Sep 10, 2026 | 291,876 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.33% | 13,695,790 | 2.64B | Jun 29, 2026 |
| Farallon Capital Management LLC | 6.27% | 13,550,796 | 2.62B | Jun 29, 2026 |
| FMR, LLC | 5.64% | 12,200,422 | 2.36B | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 5.29% | 11,443,357 | 2.21B | Jun 29, 2026 |
| Jupiter Topco LLC | 4.96% | 10,736,145 | 2.07B | Jun 29, 2026 |
| Darwin Global Management, Ltd. | 4.91% | 10,629,822 | 2.05B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.96% | 6,412,413 | 1.24B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.14% | 4,631,150 | 894.09M | Jun 29, 2026 |
| Growth Fund of America | 1.37% | 2,964,768 | 572.38M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.23% | 2,670,853 | 515.63M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.14% | 2,472,885 | 477.42M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.06% | 2,291,511 | 442.40M | Jun 29, 2026 |